NASDAQ:OVAS - OvaScience Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.99
▼ -0.04 (-3.88%)
Get New OvaScience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OVAS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OVAS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for OvaScience in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.99.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in OvaScience. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/16/2018HC WainwrightReiterated RatingBuy$15.00High
i
11/6/2017HC WainwrightReiterated RatingBuy$15.00N/A
i
8/3/2017OppenheimerReiterated RatingHoldLow
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
6/22/2017OppenheimerReiterated RatingHoldHigh
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
5/12/2017HC WainwrightReiterated RatingBuy$15.00Low
i
4/18/2017Credit Suisse GroupReiterated RatingUnderperform ➝ Underperform$1.00Low
i
3/22/2017OppenheimerReiterated RatingHoldMedium
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
3/4/2017OppenheimerReiterated RatingHoldN/A
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
12/25/2016OppenheimerReiterated RatingHoldN/A
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
12/6/2016OppenheimerReiterated RatingHoldN/A
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
11/6/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Andrew Fein at HC Wainwright
8/10/2016JMP SecuritiesReiterated RatingNeutralN/A
i
8/5/2016JPMorgan Chase & Co.Lower Price TargetNeutral$9.00 ➝ $8.00N/A
i
7/12/2016Credit Suisse GroupReiterated RatingSellN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
5/8/2016SVB LeerinkReiterated RatingHold$6.00 ➝ $7.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
4/25/2016OppenheimerReiterated RatingHoldN/A
i
(Data available from 4/18/2016 forward)
OvaScience logo
Millendo Therapeutics, Inc. engages in the development of treatments for orphan endocrine diseases. Its product pipeline includes Livoletide (AZP-531) for the treatment of Prader-Willi syndrome; Nevanimibe for classic congenital adrenal hyperplasia; and Neurokinin 3 receptor for vasomotor symptoms. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI.
Read More

Today's Range

Now: $0.99
$0.97
$1.06

50 Day Range

MA: $12.74
$8.56
$17.10

52 Week Range

Now: $0.99
$0.66
$1.52

Volume

802,844 shs

Average Volume

163,131 shs

Market Capitalization

$35.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.11

Frequently Asked Questions

What sell-side analysts currently cover shares of OvaScience?

The following sell-side analysts have issued research reports on OvaScience in the last twelve months:
View the latest analyst ratings for OVAS.

What is the current price target for OvaScience?

0 Wall Street analysts have set twelve-month price targets for OvaScience in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for OvaScience in the next year.
View the latest price targets for OVAS.

What is the current consensus analyst rating for OvaScience?

OvaScience currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for OVAS.

What other companies compete with OvaScience?

How do I contact OvaScience's investor relations team?

OvaScience's physical mailing address is 9 FOURTH AVENUE, WALTHAM MA, 02451. The biotechnology company's listed phone number is (734) 845-9000 and its investor relations email address is [email protected] The official website for OvaScience is www.ovascience.com.